
B-cell depleting agents for ANCA vasculitides: A new therapeutic approach
Keywords: AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibodies; Breg, regulatory B cells; CRP, C-reactive protein; cPR3, PR3 complementary peptide; CSS, Churg–Strauss syndrome; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; FNG